Amy Medical University of China - China
AUTHOR PROFILE
EARLY ACADEMIC PURSUITS 🎓
Professor Xiang Xu's journey in medical sciences began in China, where he displayed an early passion for cellular therapies and regenerative medicine. He earned his doctoral degree from the prestigious Third Military Medical University in 2006. His academic excellence and dedication to advancing medical research led him to pursue postdoctoral studies at Pittsburgh University from 2007 to 2009, where he explored the role of HDAC2 in promoting eIF4E sumoylation and activating mRNA translation gene specifically. These formative years laid the groundwork for his future breakthroughs in cytotherapeutics.
PROFESSIONAL ENDEAVORS 🌍
After completing his postdoctoral research, Professor Xu returned to China and became a principal investigator in the field of stem cell and regenerative medicine. In 2010, he joined the first department at the State Key Laboratory of Trauma, Burn, and Combined Injury, where he carried out groundbreaking research on cytotherapeutics. His leadership and expertise in the field positioned him as a pioneering figure in regenerative medicine.
CONTRIBUTIONS AND RESEARCH FOCUS 💡
Professor Xu has been at the forefront of developing innovative therapies in regenerative medicine. His research primarily focuses on immunocyte-based and stem cell-based therapies. In 2018, he founded the Department of Stem Cell & Regenerative Medicine at Daping Hospital of Amy Medical University, where he led multiple clinical and translational research projects. One of his most notable contributions is the development of a novel treatment strategy: the combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-gamma treatment to improve clinical outcomes for patients with rheumatoid arthritis.
ACCOLADES AND RECOGNITION 🏆
Professor Xu’s pioneering research and contributions to cytotherapeutics have earned him widespread recognition. His work has been acknowledged in the scientific community through numerous awards and honors. As a distinguished professor at Amy Medical University, his influence extends beyond research, inspiring the next generation of scientists in stem cell therapy and regenerative medicine.
IMPACT AND INFLUENCE 👨🎓
Professor Xu's research has significantly influenced the field of regenerative medicine, particularly in the treatment of autoimmune diseases. His innovative therapeutic strategies have provided new hope for patients suffering from conditions such as rheumatoid arthritis. Through his leadership in academic and medical institutions, he has mentored numerous researchers and clinicians, further advancing the field of cytotherapeutics.
LEGACY AND FUTURE CONTRIBUTIONS ⚛️
\With a strong foundation in regenerative medicine, Professor Xu continues to push the boundaries of stem cell research. His legacy is defined by his commitment to translational research and clinical applications of cytotherapeutics. His future endeavors aim to refine stem cell-based treatments, explore new regenerative strategies, and expand the possibilities of cellular therapy for various medical conditions.
VISION FOR SCIENTIFIC ADVANCEMENT 🛠️
Professor Xu envisions a future where regenerative medicine and cytotherapeutics revolutionize healthcare. His continued efforts in stem cell research and immunotherapy aim to improve treatment outcomes for patients worldwide. Through his dedication to scientific progress, he is shaping a future where cell-based therapies become a cornerstone of modern medicine.
NOTABLE PUBLICATION
-
Title: Lactate-mediated lactylation in human health and diseases: Progress and remaining challenges
Authors: Xue-ting Hu, Xiao-feng Wu, Jin-yi Xu, Xiang Xu
Journal: Journal of Advanced Research
-
Title: The dual role of mesenchymal stem cells in apoptosis regulation
Authors: Zhuo Chen, Xuewei Xia, Mengwei Yao, Yi Yang, Xiang Ao, Zhaoqi Zhang, Li Guo, Xiang Xu
Journal: Cell Death & Disease
-
Title: XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
Authors: Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang et al.
Journal: Signal Transduction and Targeted Therapy
-
Title: Effect of GRK4 on renal gastrin receptor regulation in hypertension
Authors: Xia, X.; Zeng, Y.; Li, Z.; Luo, H.; Wang, W.; He, Y.; Lu, B.; Guo, J.; Chen, K.; Xu, X.
Journal: Clinical and Experimental Hypertension
-
Title: Fibulin2: a negative regulator of BMSC osteogenic differentiation in infected bone fracture healing
Authors: Li, S.-D.; Xing, W.; Wang, S.-C.; Li, Y.-B.; Jiang, H.; Zheng, H.-X.; Li, X.-M.; Yang, J.; Guo, D.-B.; Xie, X.-Y. et al.
Journal: Experimental and Molecular Medicine
-
Title: HGF Mediates Human Gingival Derived Mesenchymal Stem Cells Alleviated Airway Inflammation in Animal Models of Allergic Asthma
Authors: Fang, Q.; Wu, W.; Xiao, Z.; Zeng, D.; Liang, R.; Wang, J.; Yuan, J.; Su, W.; Xu, X.; Zheng, Y. et al.
Journal: SSRN